Valuation : Decoy Therapeutics Inc.

Market Cap 19.52L 16.84L 15.87L 14.46L 27.02L 18Cr 27.22L 1.88Cr 72.9L 9.43Cr 73.32L 71.71L 31Cr P/E 2024 *
-
P/E 2025 -0.06x
Enterprise Value -87.57L -75.55L -71.17L -64.84L -1.21Cr -83Cr -1.22Cr -8.43Cr -3.27Cr -42Cr -3.29Cr -3.22Cr -138.94Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.52%
Yield 2024 *
-
Yield 2025 -

Last Transcript : Decoy Therapeutics Inc.

1 day-2.61%
1 week-1.00%
Current month-2.30%
1 month-27.49%
3 months-65.39%
6 months-62.43%
Current year-61.72%
1 week 2.87
Extreme 2.8701
3.29
1 month 2.85
Extreme 2.85
4.45
Current year 2.85
Extreme 2.85
16.92
1 year 2.85
Extreme 2.85
70.8
3 years 2.85
Extreme 2.85
1,368
5 years 2.85
Extreme 2.85
43,199.97
10 years 2.85
Extreme 2.85
5,33,353.97
Date Insider Type Main position Quantity % Market Cap. Importance
30/12/25 Sell

Director

27 0.0005%
20/11/25 Buy

Director

5,000 0.1402%
20/11/25 Buy

Chief Financial Officer

20,000 0.5608%
Change 5-day change 1-year change 3-year change Capi.($)
-2.61%-1.00%-95.00%-99.77% 19.52L
+1.03%-2.05%+39.28%+94.60% 6.89TCr
+1.35%+0.57%+49.51%+92.17% 6.53TCr
-0.20%+2.45%-13.33%+371.62% 2.77TCr
+2.97%+0.40%+38.60%+12.79% 2.58TCr
-0.47%-7.06%+3.10%-15.14% 2.61TCr
+1.24%+1.52%+26.66%-17.39% 2.01TCr
-0.38%-17.67%+214.37%+373.18% 1.7TCr
+0.77%-5.28%-3.25%+539.79% 1.5TCr
+0.63%+5.56%+57.83%+161.94% 1.45TCr
Average +0.45%-2.87%+31.78%+151.38% 2.8TCr
Weighted average by Cap. +0.93%-2.35%+41.45%+139.85%

Financials

2024 2025
Net sales - -
Net income -55.76L -48.1L -45.31L -41.29L -77.17L -53Cr -77.75L -5.36Cr -2.08Cr -27Cr -2.09Cr -2.05Cr -88Cr -1.25Cr -1.08Cr -1.02Cr -92.69L -1.73Cr -118.26Cr -1.75Cr -12Cr -4.67Cr -60Cr -4.7Cr -4.6Cr -198.61Cr
Net Debt -22.13L -19.09L -17.98L -16.38L -30.62L -21Cr -30.85L -2.13Cr -82.62L -11Cr -83.09L -81.27L -35Cr -1.07Cr -92.39L -87.04L -79.3L -1.48Cr -101.17Cr -1.49Cr -10Cr -4Cr -52Cr -4.02Cr -3.93Cr -169.92Cr
Logo Decoy Therapeutics Inc.
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
Employees
11
Date Price Change Volume
02/26/02 $2.980 -2.61% 9,731
01/26/01 $3.060 +0.33% 35,603
31/26/31 $3.050 +5.17% 12,450
28/26/28 $2.900 -2.36% 33,351
27/26/27 $2.970 -1.33% 17,879

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DCOY Stock